Medical artificial intelligence (AI) company Lunit has entered into a partnership with Mexican medical network Salud Digna to advance AI in medical imaging.
The collaboration is aimed at integrating Lunit’s AI-powered imaging technologies across Salud Digna’s network of over 230 clinics in Mexico and Central America.
As part of the agreement, Lunit will supply its flagship AI products, including Lunit INSIGHT CXR, a chest X-ray analysis tool, and Lunit INSIGHT MMG, a mammography analysis platform. These technologies will support Salud Digna in serving its patient base, which includes approximately 20 million individuals annually.
Salud Digna CEO Juan Carlos Ordoñez said: “By integrating Lunit’s advanced AI into our healthcare network, we aim to improve the accuracy and efficiency of our imaging services.
“Together, we are committed to leveraging our extensive data resources to drive innovation in medical imaging and ultimately improve patient care across the region.”
The partnership will also allow Lunit access to Salud Digna’s database of deidentified medical images. The data set comprises millions of 2D mammography and chest X-ray scans, which will be used to refine and localise Lunit’s AI algorithms for the Latin American healthcare market.
In addition to the deployment of these tools, the collaboration includes joint research initiatives. Both organisations plan to utilise the shared data to advance medical imaging technologies and explore further applications of AI in healthcare delivery.
Lunit and Salud Digna aim to demonstrate the potential impact of AI integration on diagnostics and treatment in Mexico and the surrounding region.
Lunit CEO Brandon Suh said: “This multifaceted partnership with Salud Digna marks a milestone in our global expansion and our mission to improve patient outcomes through AI.
“By combining our cutting-edge AI technology with Salud Digna’s vast clinical experience and extensive patient data, we’re not just supplying software – we’re collaborating to advance medical imaging AI technology tailored to the needs of patients in Mexico and potentially the broader Latin American region.”
The partnership comes on the heels of another collaboration announced by Lunit with AstraZeneca, focusing on digital pathology solutions.
Lunit’s collaboration with AstraZeneca is centred on the development of Lunit SCOPE Genotype Predictor, an AI tool designed to analyse haematoxylin and eosin (H&E) slide images to predict tumour mutations such as epidermal growth factor receptor (EGFR) alterations. These mutations are linked to non-small cell lung cancer (NSCLC), and the solution aims to enhance the precision of diagnosis and treatment planning.
